Healthcare · Medical - Devices
Price
$93.82
Market Cap
$163.4B
Employees
114,000
Beta
0.62
Avg Volume
12,996,206
CEO
Robert Ford
Business Description
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
Business History
Price Overview
Last updated: Jun 27, 2026 8:59am (just now)$93.82
+0.58 (+0.62%)
Day Range
$93.21 – $95.21
52-Week Range
$81.97 – $137.49
50-Day MA
$89.27
200-Day MA
$112.80
Volume
15,522.00
Analyst Price Targets
Low
$92.00
Consensus
$126.00
High
$152.00
(70 analysts)
Share Structure
Outstanding
1,741,810,000.00
Float
1,729,986,593.00
Free Float
99.3%
High free float
— 99.3% of shares trade freely, ~0.7% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
APIStock Price / EPS (Diluted)
26.12
Stock Price: $93.82
EPS (Diluted): 3.74
EPS (Diluted): 3.74
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
4.20
Stock Price: $93.82
Total Equity: $52.13B
Shares: 1,747,000,000
Total Equity: $52.13B
Shares: 1,747,000,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
17.01
Market Cap: $163.42B
Total Debt: $14.14B
Cash: $8.52B
EBITDA: $11.55B
Total Debt: $14.14B
Cash: $8.52B
EBITDA: $11.55B
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$225.4B
Market Cap: $163.42B
Total Debt: $14.14B
Cash: $8.52B
Total Debt: $14.14B
Cash: $8.52B
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
55.5%
Gross Profit: $24.61B
Revenue: $44.33B
Revenue: $44.33B
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
18.2%
Operating Income: $8.05B
Revenue: $44.33B
Revenue: $44.33B
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
14.7%
Net Income: $6.52B
Revenue: $44.33B
Revenue: $44.33B
ROE (Profit from shareholder equity)
APINet Income / Total Equity
12.2%
Net Income: $6.52B
Total Equity: $52.13B
Total Equity: $52.13B
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
6.6%
Operating Income: $8.05B
Tax Rate: 22.9%
Equity: $52.13B
Total Debt: $14.14B
Cash: $8.52B
Tax Rate: 22.9%
Equity: $52.13B
Total Debt: $14.14B
Cash: $8.52B
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
1.58
Current Assets: $26.00B
Current Liabilities: $16.50B
Current Liabilities: $16.50B
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.27
Short-Term Debt: $3.31B
Long-Term Debt: $10.83B
Total Debt: $14.14B
Total Equity: $52.13B
Long-Term Debt: $10.83B
Total Debt: $14.14B
Total Equity: $52.13B
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$25.37
Revenue: $44.33B
Shares: 1,747,000,000
Shares: 1,747,000,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$29.84
Total Equity: $52.13B
Shares: 1,747,000,000
Shares: 1,747,000,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$4.23
Operating CF: $9.57B
CapEx: -$2.17B
Shares: 1,747,000,000
CapEx: -$2.17B
Shares: 1,747,000,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
1.9%
Last Dividend: N/A
Stock Price: $93.82
Stock Price: $93.82
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: $6.52B
Net Income: $6.52B
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares ABT against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 25, 2026 3:03am (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $43.1B | $43.7B | $40.1B | $42.0B | $44.3B |
| Cost of Revenue | $19.9B | $21.3B | $20.1B | $20.6B | $19.7B |
| Gross Profit | $23.2B | $22.3B | $20.0B | $21.3B | $24.6B |
| Operating Expenses | $14.0B | $14.0B | $13.6B | $14.5B | $16.6B |
| Operating Income | $9.2B | $8.4B | $6.4B | $6.8B | $8.0B |
| Net Income | $7.1B | $6.9B | $5.7B | $13.4B | $6.5B |
| EBITDA | $12.2B | $11.9B | $10.6B | $10.8B | $11.6B |
| EPS | $3.97 | $3.94 | $3.30 | $7.67 | $3.74 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 23, 2026 3:02am (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $9.8B | $9.9B | $6.9B | $7.6B | $8.5B |
| Total Current Assets | $24.2B | $25.2B | $22.7B | $23.7B | $26.0B |
| Total Assets | $75.2B | $74.4B | $73.2B | $81.4B | $86.7B |
| Current Liabilities | $13.1B | $15.5B | $13.8B | $14.2B | $16.5B |
| Long-Term Debt | $17.3B | $14.5B | $13.6B | $12.6B | $10.8B |
| Total Liabilities | $39.2B | $37.5B | $34.4B | $33.5B | $33.9B |
| Total Equity | $35.8B | $36.7B | $38.6B | $47.7B | $52.1B |
| Retained Earnings | $31.5B | $35.3B | $37.6B | $47.3B | $49.8B |
Cash Flow (Annual)
Last updated: Jun 25, 2026 3:04am (2d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $10.5B | $9.6B | $7.3B | $8.6B | $9.6B |
| Capital Expenditure | -$1.9B | -$1.8B | -$2.2B | -$2.2B | -$2.2B |
| Free Cash Flow | $8.6B | $7.8B | $5.1B | $6.4B | $7.4B |
| Acquisitions (net) | -$53.0M | $48.0M | -$837.0M | $1.0M | -$105.0M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$2.3B | -$3.8B | -$1.2B | -$1.3B | -$893.0M |
| Net Change in Cash | $3.0B | $83.0M | -$3.0B | $720.0M | $906.0M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 8:40am (18m ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$54.9B $54.2B – $55.4B
|
$58.9B $58.8B – $59.0B
|
$63.4B $61.4B – $63.9B
|
$68.2B $66.1B – $68.7B
|
| EBITDA |
$14.7B $14.5B – $14.8B
|
$15.8B $15.7B – $15.8B
|
$17.0B $16.4B – $17.1B
|
$18.3B $17.7B – $18.4B
|
| Net Income |
$10.6B $10.4B – $10.7B
|
$9.2B $8.7B – $13.7B
|
$13.2B $12.6B – $13.3B
|
$14.6B $14.0B – $14.7B
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 25, 2026 3:03am (2d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +1.3% | -8.1% | +4.6% | +5.7% |
| Gross Profit Growth | -3.8% | -10.2% | +6.4% | +15.4% |
| Operating Income Growth | -9.1% | -23.0% | +6.1% | +17.9% |
| Net Income Growth | -2.0% | -17.5% | +134.2% | -51.3% |
| EBITDA Growth | -2.2% | -10.8% | +2.2% | +6.6% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 8:40am (18m ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-05-07 | Stratton John G | P-Purchase | 2,000.00 | $86.82 | $173,640 |
| 2026-04-28 | Moreland Mary K | I-Discretionary | 5,314.00 | $94.41 | $501,695 |
| 2026-04-24 | Conroy Kevin T | A-Award | 2,286.00 | $0.00 | $0 |
| 2026-04-24 | Conroy Kevin T | 0.00 | $0.00 | $0 | |
| 2026-04-24 | Stratton John G | A-Award | 2,286.00 | $0.00 | $0 |
| 2026-04-27 | STARKS DANIEL J | P-Purchase | 10,000.00 | $92.65 | $926,537 |
| 2026-04-24 | STARKS DANIEL J | A-Award | 2,286.00 | $0.00 | $0 |
| 2026-04-24 | STARKS DANIEL J | A-Award | 7,105.00 | $91.86 | $652,665 |
| 2026-04-24 | Roman Michael F | A-Award | 2,286.00 | $0.00 | $0 |
| 2026-04-24 | O'Grady Michael | A-Award | 2,286.00 | $0.00 | $0 |
| 2026-04-24 | O'Grady Michael | A-Award | 5,929.00 | $91.86 | $544,638 |
| 2026-04-24 | McKinstry Nancy | A-Award | 2,286.00 | $0.00 | $0 |
| 2026-04-24 | McKinstry Nancy | A-Award | 2,305.00 | $91.86 | $211,737 |
| 2026-04-24 | McDew Darren W | A-Award | 2,286.00 | $0.00 | $0 |
| 2026-04-24 | Kumbier Michelle | A-Award | 2,286.00 | $0.00 | $0 |
| 2026-04-24 | Gonzalez Patricia Paola | A-Award | 2,286.00 | $0.00 | $0 |
| 2026-04-24 | Blount Sally E. | A-Award | 2,286.00 | $0.00 | $0 |
| 2026-04-24 | Babineaux-Fontenot Claire | A-Award | 2,286.00 | $0.00 | $0 |
| 2026-04-24 | Ahuja Nita | A-Award | 2,286.00 | $0.00 | $0 |
| 2026-04-23 | Boudreau Philip P | I-Discretionary | 8,909.00 | $92.04 | $819,984 |
Dividend History (Last 20)
Last updated: Jun 21, 2026 6:57pm (5d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-07-15 | $0.63 | 2026-06-12 | 2026-07-15 | 2026-08-17 |
| 2026-04-15 | $0.63 | 2026-02-20 | 2026-04-15 | 2026-05-15 |
| 2026-01-15 | $0.63 | 2025-12-12 | 2026-01-15 | 2026-02-13 |
| 2025-10-15 | $0.59 | 2025-09-19 | 2025-10-15 | 2025-11-17 |
| 2025-07-15 | $0.59 | 2025-06-13 | 2025-07-15 | 2025-08-15 |
| 2025-04-15 | $0.59 | 2025-02-21 | 2025-04-15 | 2025-05-15 |
| 2025-01-15 | $0.59 | 2024-12-13 | 2025-01-15 | 2025-02-14 |
| 2024-10-15 | $0.55 | 2024-09-19 | 2024-10-15 | 2024-11-15 |
| 2024-07-15 | $0.55 | 2024-06-14 | 2024-07-15 | 2024-08-15 |
| 2024-04-12 | $0.55 | 2024-02-16 | 2024-04-15 | 2024-05-15 |
| 2024-01-11 | $0.55 | 2023-12-15 | 2024-01-12 | 2024-02-15 |
| 2023-10-12 | $0.51 | 2023-09-21 | 2023-10-13 | 2023-11-15 |
| 2023-07-13 | $0.51 | 2023-06-09 | 2023-07-14 | 2023-08-15 |
| 2023-04-13 | $0.51 | 2023-02-17 | 2023-04-14 | 2023-05-15 |
| 2023-01-12 | $0.51 | 2022-12-09 | 2023-01-13 | 2023-02-15 |
| 2022-10-13 | $0.47 | 2022-09-15 | 2022-10-14 | 2022-11-15 |
| 2022-07-14 | $0.47 | 2022-06-10 | 2022-07-15 | 2022-08-15 |
| 2022-04-13 | $0.47 | 2022-02-18 | 2022-04-15 | 2022-05-16 |
| 2022-01-13 | $0.47 | 2021-12-10 | 2022-01-14 | 2022-02-15 |
| 2021-10-14 | $0.45 | 2021-09-15 | 2021-10-15 | 2021-11-15 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for ABT — it's generated by the pipeline (
market-narrative step).
No community reviews yet for ABT.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30